How to Get Leqvio (Inclisiran) in Georgia

What Is Leqvio and Why Georgia Patients Are Seeking It

Leqvio is a small interfering RNA (siRNA) drug that silences the PCSK9 gene in hepatocytes, cutting LDL-receptor degradation and dropping LDL-cholesterol by roughly 50% between doses. Unlike daily statins, it is injected subcutaneously in a clinical office on day 1, day 90, and then once every six months. The FDA approved inclisiran in December 2021 for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), who need additional LDL-lowering on top of maximally tolerated statin therapy. [1]

Georgia has a cardiovascular disease burden above the national average. [2] That combination of clinical need and a once or twice-yearly dosing schedule has made inclisiran one of the fastest-growing specialty lipid prescriptions in the Southeast.

The two key trials, ORION-10 (N=1,561, U.S. patients only) and ORION-11 (N=1,617, Europe/U.S.), both published in the New England Journal of Medicine in 2020, showed time-adjusted mean LDL-C reductions of 52.3% and 49.9% respectively vs. placebo at 510 days (P<0.001 for both). [3] Adverse event rates between inclisiran and placebo were statistically similar, with injection-site reactions the most common drug-related complaint (2.6% inclisiran vs. 0.9% placebo in ORION-10). [3]

Who Can Prescribe Leqvio in Georgia

Any Georgia-licensed MD, DO, nurse practitioner (NP), or physician assistant (PA) operating within their scope of practice may prescribe inclisiran. Georgia NPs practice under a collaborative agreement for the first two years of independent practice but may prescribe Schedule III-V controlled substances and non-controlled specialty drugs. Inclisiran is not a controlled substance. PAs in Georgia prescribe under physician supervision per O.C.G.A. § 43-34-103.

Specialists who most commonly initiate inclisiran include:

• Preventive cardiologists who manage refractory hypercholesterolemia post-ACS.
• Lipidologists certified through the American Board of Clinical Lipidology.
• Endocrinologists managing familial hypercholesterolemia alongside metabolic disorders.
• Primary care physicians who have completed prior authorization and have an in-office or contracted infusion site for the injection.

The 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction states: "For patients with ASCVD who require additional LDL-C lowering despite maximally tolerated statin and ezetimibe, PCSK9 inhibitors including inclisiran are recommended (Class I, LOE: A)." [4]

Telehealth Access to Leqvio in Georgia

Georgia permits telemedicine prescribing of non-controlled specialty drugs. A telehealth clinician may evaluate your lipid history, review prior labs, and generate the prescription electronically. The injection itself must still be performed in a clinical setting because inclisiran is not a self-injection drug.

A practical telehealth pathway looks like this:

1. Schedule a video visit with a Georgia-licensed telehealth provider (HealthRX clinicians are licensed in Georgia).
2. Upload your most recent fasting lipid panel, current statin dose, and any prior PCSK9 inhibitor history.
3. Receive an electronic prescription and a referral to a participating infusion center, cardiology office, or specialty pharmacy that administers injections.
4. The specialty pharmacy ships inclisiran directly to the administering clinical site. You attend your injection appointment.

The Georgia Composite Medical Board explicitly allows prescribing via synchronous video evaluation provided the clinician establishes a valid patient-provider relationship during the visit. A telephone-only encounter without video does not meet that standard for a new specialty prescription.

Labs and Workup Required Before Starting Leqvio

Baseline labs serve two purposes: confirming eligibility and establishing a pre-treatment LDL-C that payers will require for prior authorization.

Minimum required labs:

• Fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides). Must be obtained within 12 months; most payers require a result within 3 to 6 months.
• LFTs (AST/ALT) to screen for active liver disease, which is a contraindication.
• Calculated 10-year ASCVD risk via the Pooled Cohort Equations if the indication is primary prevention or borderline risk.

Labs that support prior authorization approval but are not required for safety:

• A second fasting LDL-C drawn 4 to 12 weeks after maximum statin dose adjustment confirms statin intolerance or residual risk.
• Genetic testing showing an LDL receptor or APOB variant strengthens the HeFH diagnosis for payer review.

A 2023 JAMA analysis noted that patients denied PCSK9 inhibitor therapy due to incomplete documentation had a 34% higher rate of resubmission delays compared to those who provided two documented LDL-C values above the payer threshold at submission. [5]

Prior Authorization: What Georgia Payers Require

Prior authorization (PA) is required by nearly every commercial insurer and pharmacy benefit manager for inclisiran in Georgia. Georgia Medicaid does not cover inclisiran for FH or ASCVD indications as of January 2025.

Standard PA documentation checklist for Georgia commercial plans:

| Requirement | Typical threshold | |---|---| | LDL-C on maximally tolerated statin | 70 mg/dL or higher (ASCVD), 100 mg/dL or higher (HeFH) | | Statin trial duration | At least 3 months at maximum tolerated dose | | Ezetimibe trial | Required by most plans before PCSK9 approval | | Documented ASCVD event or HeFH diagnosis | Cardiology note, genetic report, or hospital discharge summary | | Prescriber specialty | Some plans require cardiologist or lipidologist initiation |

Blue Cross Blue Shield of Georgia, Cigna, and United Healthcare all follow the ACC/AHA 2022 PCSK9 pathway for coverage determination. Aetna Better Health Georgia (Medicaid MCO) currently excludes inclisiran for lipid indications outside T2D.

The PA process takes 3 to 14 business days. Step therapy (statin plus ezetimibe failure) is required by most plans before inclisiran will be approved.

According to the American Heart Association's 2023 cholesterol management update: "Access barriers including step therapy and prior authorization requirements continue to delay initiation of guideline-directed PCSK9 inhibitor therapy by an average of 4.3 months." [6]

How Long Until You Receive Leqvio in Georgia

Expect 2 to 6 weeks from your initial consultation to your first injection, assuming prior authorization is approved on first submission.

A realistic timeline:

• Days 1 to 3. Telehealth or in-person visit, labs ordered if not already on file.
• Days 4 to 10. Lab results returned, PA submitted to payer.
• Days 10 to 24. PA decision (3 to 14 business days per Georgia Insurance Commissioner standard turnaround).
• Days 25 to 35. Specialty pharmacy receives approved PA, ships drug to clinical site, appointment scheduled for first injection.

Patients with an active appeal or denial add 2 to 4 weeks. Novartis offers a patient assistance program, Leqvio Together, that may reduce out-of-pocket cost to $0 for eligible commercially insured patients and can provide drug while an appeal is pending. [1]

Transferring a Leqvio Prescription to Georgia

If you are relocating to Georgia or switching providers, the process is straightforward. Inclisiran prescriptions are tied to the administering clinical site rather than a retail pharmacy. The steps:

1. Obtain your treatment records, including your original indication, last injection date, and PA approval letter from your prior state.
2. Establish care with a Georgia-licensed prescriber (in-person or telehealth).
3. The new prescriber submits a fresh PA to your current insurer using your existing documentation. Most Georgia plans will accept a prior out-of-state PA as supporting evidence, shortening the new review to 3 to 5 business days.
4. The new clinical site or specialty pharmacy takes over your injection schedule.

You do not "transfer" the prescription itself the way you would with a retail statin. The prescriber generates a new order in Georgia. Your injection schedule continues from wherever you left off. If your last injection was 4 months ago, your next dose is due in 2 months, and a Georgia clinician may give that dose after reviewing your records.

503A Pharmacy Options for Inclisiran in Georgia

503A compounding pharmacies in Georgia are licensed by the Georgia Board of Pharmacy and may compound inclisiran with a valid patient-specific prescription from a licensed prescriber. Compounded inclisiran is not FDA-approved and does not carry Novartis quality controls.

Clinically, the difference matters. The FDA-approved Leqvio is manufactured under rigorously validated GMP conditions and the ORION trial data apply specifically to that formulation. Compounded inclisiran may differ in excipients, tonicity, or concentration. No randomized trial has evaluated a compounded inclisiran preparation.

Compounded inclisiran from a 503A pharmacy in Georgia might be appropriate in two narrow situations:

• Commercial insurance denial after exhausting appeals, with the patient unable to access the Novartis patient assistance program.
• Patients with a documented allergy to an excipient in the branded formulation who need a modified preparation.

In either case, the prescribing clinician should document the medical necessity for compounding specifically. The Georgia Board of Pharmacy requires that 503A pharmacies compound only in response to a valid individual prescription and not for office-use stock of inclisiran.

What the Injection Visit Looks Like

Inclisiran 284 mg is injected subcutaneously, typically in the abdomen, upper arm, or thigh, by a trained clinical staff member. The injection takes under 2 minutes. Patients are generally observed for 30 minutes afterward for any local or systemic reaction, though serious reactions have been exceedingly rare in trial data.

No premedication is needed. Patients continue their statin and any other lipid-lowering agents. After the day-1 and day-90 loading injections, the maintenance schedule is one injection every 6 months. Missing a dose by up to 3 months does not require restarting the loading sequence; the injection may be given and the 6-month schedule continues from that date.

The LDL-C lowering becomes measurable within 30 days and reaches its nadir around day 60 to 90. Because the siRNA mechanism silences PCSK9 production at the mRNA level, the effect persists between injections without the trough-to-peak variability seen with daily oral agents. [3]

Cost and Coverage Summary for Georgia Patients

| Payer type | Inclisiran coverage status (GA, 2025) | |---|---| | Commercial (BCBS GA, Cigna, UHC, Aetna commercial) | Covered with PA and step therapy | | Georgia Medicaid (fee-for-service) | Not covered for FH/ASCVD | | Medicaid MCOs (Aetna Better Health GA, Amerigroup GA, Molina GA) | Not covered for FH/ASCVD | | Medicare Part B | Covered when administered in physician office (drug is buy-and-bill) | | Medicare Part D | Generally not covered (Part B buy-and-bill pathway preferred) | | Novartis Leqvio Together (patient assistance) | $0 copay for eligible commercially insured; free drug for uninsured meeting income criteria |

Medicare Part B coverage is a practical advantage for Georgia seniors. Because inclisiran is administered in a physician office rather than self-injected at home, it falls under Part B (medical benefit) rather than Part D (pharmacy benefit). Part B coinsurance after deductible is typically 20%, which is substantially lower than a Part D specialty tier copay for most beneficiaries.

Monitoring After Starting Leqvio

After the first injection, a fasting lipid panel at 60 to 90 days confirms the LDL-C response. A reduction of at least 40% from baseline is expected. If the reduction is less than 30%, the prescriber should verify statin adherence and assess for secondary causes of hypercholesterolemia (hypothyroidism, nephrotic syndrome, obstructive liver disease).

Ongoing labs per ACC/AHA 2022 guidance:

• Fasting lipid panel every 6 to 12 months once on stable therapy. [4]
• LFTs are not required on a routine schedule unless the patient has pre-existing liver disease.
• No renal dose adjustment is needed for inclisiran; ORION-7 (N=30) showed no clinically meaningful pharmacokinetic change in severe renal impairment. [7]

Long-term safety data now extend to 5 years from the ORION-3 open-label extension (N=290), which showed sustained LDL-C reduction of approximately 45% with no new safety signals compared to the parent trial. [8]